Olivia G. Kelly, Ph.D.

VP, Head of Islet Cell Therapy Research

Dr. Olivia G. Kelly has over 13 years of experience in the biotechnology industry developing cell therapies. Prior to joining Sigilon, Dr. Kelly served as the Senior Director of Cell Biology at ViaCyte, a clinical stage company focused on developing stem cell-derived therapies for diabetes, where she led efforts in stem cell differentiation, assay development, quality control and tumorigenicity studies which supported multiple IND/CTA filings and achieved multiple research grant and licensing milestones. Dr. Kelly has coauthored a number of high-profile journal publications and is a co-inventor on multiple patents.

Dr. Kelly earned a B.S. in Molecular Biology from the University of Texas at Austin and then pursued a Ph.D. in Biochemistry and Molecular Biology from Harvard University, where her research focused on molecular mechanisms of early embryonic patterning and pancreas development. Dr. Kelly’s postdoctoral fellowships at the University of California at Berkeley/San Francisco and Baylor College of Medicine focused on signaling mechanisms that regulate the development of various tissues and stem cell differentiation.

‹ Back